API | etalocib

etalocib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Etalocib is a drug candidate that was under development for the treatment of various types of cancer. It acts as a leukotriene B4 receptor antagonist and a PPARγ agonist. ^Wikipedia

Chemistry

SMILES: CCCc1c(OCCCOc2cc(O)c(cc2CC)c3ccc(F)cc3)cccc1Oc4ccccc4C(=O)O
InChIKey: YFIZRWPXUYFCSN-UHFFFAOYSA-N
Mol. Mass: 544.62
ALogP: 8.05 Partition coefficient
ChEMBL Molecule:
etalocib

More Chemistry

Pharmacology

Mechanisms of Action:
- Leukotriene B4 receptor 1 (Homo sapiens) ^UniProt
- Peroxisome proliferator-activated receptor gamma (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(2-propyl-3-(3-(2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy)propoxy)phenoxy)benzoic acid | etalocib | ly-193111 | ly293111 | ly 293111 | ly-293111 | vml295 | vml-295

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue